Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36049357)

  • 1. The elevated D-2-hydroxyglutarate level found as a characteristic metabolic change of colon cancer in both in vitro and in vivo models.
    Atalay EB; Kayali HA
    Biochem Biophys Res Commun; 2022 Oct; 627():191-199. PubMed ID: 36049357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type IDH1 Knockout Leads to G0/G1 Arrest, Impairs Cancer Cell Proliferation, Altering Glycolysis, and the TCA Cycle in Colon Cancer.
    Atalay EB; Senturk S; Kayali HA
    Biochem Genet; 2023 Aug; 61(4):1470-1486. PubMed ID: 36633771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
    Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG
    Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
    Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
    J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
    J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
    Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
    Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
    Berger RS; Ellmann L; Reinders J; Kreutz M; Stempfl T; Oefner PJ; Dettmer K
    Sci Rep; 2019 May; 9(1):7436. PubMed ID: 31092874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate.
    Rakheja D; Boriack RL; Mitui M; Khokhar S; Holt SA; Kapur P
    Tumour Biol; 2011 Apr; 32(2):325-33. PubMed ID: 21080253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
    Fathi AT; Sadrzadeh H; Comander AH; Higgins MJ; Bardia A; Perry A; Burke M; Silver R; Matulis CR; Straley KS; Yen KE; Agresta S; Kim H; Schenkein DP; Borger DR
    Oncologist; 2014 Jun; 19(6):602-7. PubMed ID: 24760710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
    Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
    Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
    Wahl DR; Venneti S
    Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced
    Li T; Cox CD; Ozer BH; Nguyen NT; Nguyen HN; Lai TJ; Li S; Liu F; Kornblum HI; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    Mol Cancer Res; 2018 Jun; 16(6):947-960. PubMed ID: 29545476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
    Suijker J; Baelde HJ; Roelofs H; Cleton-Jansen AM; Bovée JV
    Oncotarget; 2015 Jun; 6(17):14832-42. PubMed ID: 26046462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
    Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S
    J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.